These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

32 related articles for article (PubMed ID: 15130414)

  • 1. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma.
    Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
    Haematologica; 2000 Jun; 85(6):613-8. PubMed ID: 10870118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of 18F-FDG Pet/CT and CT: diagnosis performance in lymphoma patient after treatment.
    Chiewvit S; Thephamongkhol K; Ubolnuch K; Pooliam J; Phongsawat N; Chiewvit P
    J Med Assoc Thai; 2014 Jan; 97(1):85-94. PubMed ID: 24701734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
    Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
    Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of 18F-FDG coincidence SPECT imaging and computed tomography in the initial staging and therapeutic evaluation of lymphomas].
    Qiao WL; Zhao JH; Wang C; He ZY; Wang TS; Xing Y
    Zhonghua Zhong Liu Za Zhi; 2007 Jul; 29(7):536-9. PubMed ID: 18069637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-FDG PET and PET/CT in Burkitt's lymphoma.
    Karantanis D; Durski JM; Lowe VJ; Nathan MA; Mullan BP; Georgiou E; Johnston PB; Wiseman GA
    Eur J Radiol; 2010 Jul; 75(1):e68-73. PubMed ID: 19716248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regional nodal staging with 18F-FDG PET-CT in non-small cell lung cancer: Additional diagnostic value of CT attenuation and dual-time-point imaging.
    Li M; Wu N; Liu Y; Zheng R; Liang Y; Zhang W; Zhao P
    Eur J Radiol; 2012 Aug; 81(8):1886-90. PubMed ID: 21511421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical value of 18F-FDG PET-CT in detecting primary tumor for patients with carcinoma of unknown primary.
    Han A; Xue J; Hu M; Zheng J; Wang X
    Cancer Epidemiol; 2012 Oct; 36(5):470-5. PubMed ID: 22504050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (18)F-FDG-PET/CT versus panendoscopy for the detection of synchronous second primary tumors in patients with head and neck squamous cell carcinoma.
    Haerle SK; Strobel K; Hany TF; Sidler D; Stoeckli SJ
    Head Neck; 2010 Mar; 32(3):319-25. PubMed ID: 19626642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.
    Kostakoglu L; Coleman M; Leonard JP; Kuji I; Zoe H; Goldsmith SJ
    J Nucl Med; 2002 Aug; 43(8):1018-27. PubMed ID: 12163626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison of ¹⁸F-FDG PET/CT and large-scale DWI for evaluation of non-Hodgkin lymphoma bone marrow infiltration].
    Tang R; Gui S; Li J; Zhang H; Lu B; Yang P; Fu D; Fu W; Li W; Cai L
    Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):231-5. PubMed ID: 24666490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of (18)F-FDG dual-head gamma-camera coincidence imaging in recurrent or metastatic colorectal carcinoma.
    Even-Sapir E; Lerman H; Figer A; Rabau M; Livshitz G; Inbar M; Gutman M
    J Nucl Med; 2002 May; 43(5):603-9. PubMed ID: 11994521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta-2 microglobulin as a diagnostic parameter in non-Hodgkin lymphoma: a comparative study with FDG-PET.
    Toth DF; Raderer M; Wadsak W; Karanikas G
    Anticancer Res; 2013 Aug; 33(8):3341-5. PubMed ID: 23898101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elucidation of acute renal failure due to recurrent non-Hodgkin lymphoma by F-18 FDG PET/CT.
    Rozalli FI; Chua SC; Green DJ
    Clin Nucl Med; 2008 Mar; 33(3):201-3. PubMed ID: 18287847
    [No Abstract]   [Full Text] [Related]  

  • 15. Hypermetabolic change as a possible predictive sign of a relapsed central nervous system lymphoma.
    Nakahara T; Takagi Y; Shiga H; Uchida H; Kaburaki J; Kubo A
    Clin Nucl Med; 2007 Feb; 32(2):87-9. PubMed ID: 17242558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Normal and Abnormal Patterns of (18)F-Fluorodeoxyglucose PET/CT in Lymphoma.
    Bar-Shalom R
    PET Clin; 2006 Jul; 1(3):231-42. PubMed ID: 27157362
    [No Abstract]   [Full Text] [Related]  

  • 17. PET Assessment of Lymphoma: Beyond (18)F-Fluorodeoxyglucose.
    Reske S
    PET Clin; 2006 Jul; 1(3):275-81. PubMed ID: 27157366
    [No Abstract]   [Full Text] [Related]  

  • 18. Is
    Barrington SF; Cottereau AS; Zijlstra JM
    J Nucl Med; 2024 Feb; 65(4):510-1. PubMed ID: 38388515
    [No Abstract]   [Full Text] [Related]  

  • 19. [The clinical application of 18F-fluorodeoxyglucose coincidence imaging in lymphoma].
    Wang RF; Zhang XM; Zhang CL; Fu ZL; Fan Y; Cen XN
    Zhonghua Nei Ke Za Zhi; 2004 Apr; 43(4):284-7. PubMed ID: 15130414
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.